There is a paucity of real-world data regarding lenvatinib for locally-recurrent, metastatic and RAI-refractory thyroid cancer.
Here we examined the efficacy of first-line lenvatinib in a genomically-characterized cohort and identified clinicopathological/molecular correlates of drug response.
